SHA: 688382

Cutia Therapeutics Secures Macao Marketing Approval for CU‑40102 Topical Finasteride Spray – Completing Greater China Rollout in Androgenetic Alopecia
CompanyDrug

Cutia Therapeutics Secures Macao Marketing Approval for CU‑40102 Topical Finasteride Spray – Completing Greater China Rollout in Androgenetic Alopecia

Cutia Therapeutics (HKG: 2487) announced that CU‑40102, its topical finasteride spray, has been approved for marketing in Macao, China, for the treatment of androgenetic alopecia – extending the product's Greater…

Qilu Pharmaceutical Drops RMB 400 Million Equity Stake in TYK Medicines – But TY‑9591 Licensing and China Commercialization Deal Stays Alive

Qilu Pharmaceutical Drops RMB 400 Million Equity Stake in TYK Medicines – But TY‑9591 Licensing and China Commercialization Deal Stays Alive

US Treasury Drafts China Pharma Investment Rules Likely to Preserve Licensing Deals – A Carve‑Out From Broader National‑Security Tightening

US Treasury Drafts China Pharma Investment Rules Likely to Preserve Licensing Deals – A Carve‑Out From Broader National‑Security Tightening

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Explore Now
CompanyDrug

Betta Pharmaceuticals’ Befotertinib Approved by China’s NMPA for EGFR-Mutated NSCLC

CompanyLegal / IP

Mirati Therapeutics Sues InventisBio Over Trade Secret Misappropriation

CompanyDeals

InventisBio Raises USD 308M in Shanghai STAR IPO, Valued at USD 1.54B

Show More